ASCO 2017 | Is inotuzumab ozogamicin with low-dose chemotherapy effective in treating ALL in elderly patients?

Susan O’Brien

Susan O’Brien, MD from the University of California, Irvine, CA discusses the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. The outcomes of a Phase II trial involving the administration of inotuzumab ozogamicin with low-dose chemotherapy in treating elderly ALL patients who have suffered from relapses, is discussed in this segment (NCT01230788).

Share this video